News

Global CannaVigilance Cannabis Newsletter 2022 / 4

February 16, 2022 | Category : Global CannaVigilance | Posted By : Deon Maas

Hello friends of CannaVigilance,  

It is with great pleasure that we start to share with you our strategic partners that we are working with around the globe. The first partner we would like to talk about is Healthy Choice Farm, you will learn more about this collaboration later in this newsletter. But first, let’s take a closer look at what’s happening in Germany and Colombia.  

Germany Country Report 

The International Cannabis Business Conference estimates that Germany will become the largest market for medical cannabis in Europe by 2023. A first step towards this was taken when the new government that took office in Germany in December 2021 made an election promise that it would legalize the recreational use of cannabis for adults. Right now, cannabis is legal for medical purposes, and businesses operating in this area must comply with a number of standards and regulations. 

For an overview of these standards, the current state of legislation, and information on the cultivation of cannabis in Germany, read here our latest country report.  

A talk with David Garcia 

David Garcia is the Managing Partner of our client Armadillo Botanics. The company is invested in sustainable agriculture and social impact with large-scale cannabis production operation in Colombia. The land and facilities are able to organically harvest and process Cannabis plant material, ready for export, to be used in CBD/THC products in multiple sectors. In our latest article on the website, we discussed with David why growing cannabis was never on his agenda, why sustainability is critical to his business, and how Cannavigia has contributed to his success. 

Read the article here.  

Healthy Choice Farm: our newest partner 

Earlier this month, we signed a Memorandum of Understanding (MoU) with Healthy Choice Farm to support the technological development of hemp and cannabis cooperatives in Thailand through our Cannavigia software. The signing of this MoU marks our first entry into Thailand, with the objective of facilitating compliance and transparency for all stakeholders in this new market. We will be sharing more on our Website and LinkedIn page soon – follow us and never miss an update!

A vigilant eye on cannabis news:  

  • Australia’s Department of Health, preparing to overhaul its medical cannabis regulations, is poised to require that all products imported into the country be produced in accordance with Good Manufacturing Practice. The move would effectively shut out non-GMP-compliant manufacturers. Read more here.  
  • Africa’s first cannabis-focused blank-cheque company is set to list later this year with a view to buying companies in the fledgling industry alongside genetics and wearable health-device companies in the US and South Africa. Gabriel Theron, the founder of South Africa’s Cilo Cybin Pharmaceutical Ltd., aims to sell shares in a special purpose acquisition company in Johannesburg in May. Read more here.  
  • In Israel’s Negev desert the town of Yeruham hopes to cultivate an international reputation as the country’s medical cannabis technology powerhouse. Led by a firm called CanNegev, the company is known as an incubator, helping foster the growth of infant firms. CanNegev shelters four startups and is Israel’s first medical cannabis technology incubator. Read more here.  
  • Police in North Macedonia have raided a company legally growing marijuana for medicinal purposes and seized about 1.5 tons of cannabis due to “irregularities” in the firm’s operation. Read more here.   

Newsletter Sign-up

Comments

3 thoughts on “Global CannaVigilance Cannabis Newsletter 2022 / 4

  1. This is the right website for anybody who wants to find out about this topic. You understand a whole lot its almost tough to argue with you (not that I personally would want toÖHaHa). You definitely put a new spin on a topic which has been written about for years. Excellent stuff, just excellent!

Leave a Reply

Your email address will not be published.